iBio receives Australian approval for Phase 1 trial of IBIO-600
iBio Inc. (NASDAQ: IBIO) received regulatory clearance from Australia's Therapeutic Goods Administration and ethics approval from a Human Research Ethics ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
